EUVIMEDEUVIMED entdecken
Open Access

Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6

Safa Baris, Mehdi Benamar, Qian Chen, Mehmet Cihangir Catak, Mónica Martínez-Blanco, Muyun Wang, Jason Fong, Michel J Massaad, Asena Pinar Sefer, Altan Kara, Royala Babayeva, Sevgi Bilgic Eltan und 9 weitere

Journal of Allergy and Clinical Immunology · 2023-07 · 152 (1) · 182-194.e7

DOI: 10.1016/j.jaci.2023.01.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-07. Verfasst von Safa Baris und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Allergy and Immunology School of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Researc…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Hypersensitivity, Eosinophilia. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, Scientific and Technological Research Council of Turkey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inborn errors of immunity have been implicated in causing immune dysregulation, including allergic diseases. STAT6 is a key regulator of allergic responses. OBJECTIVES: This study sought to characterize a novel gain-of-function STAT6 mutation identified in a child with severe allergic manifestations. METHODS: Whole-exome and targeted gene sequencing, lymphocyte characterization, and molecular and functional analyses of mutated STAT6 were performed. RESULTS: This study reports a child with a missense mutation in the DNA binding domain of STAT6 (c.1114G>A, p.E372K) who presented with severe atopic dermatitis, eosinophilia, and elevated IgE. Naive lymphocytes from the affected patient displayed increased TH2- and suppressed TH1- and TH17-cell responses. The mutation augmented both basal and cytokine-induced STAT6 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reversed STAT6 hyperresponsiveness to IL-4, normalized TH1 and TH17 cells, suppressed the eosinophilia, and improved the patient's atopic dermatitis. CONCLUSIONS: This study identified a novel inborn error of immunity due to a STAT6 gain-of-function mutation that gave rise to severe allergic dysregulation. Janus kinase inhibitor therapy could represent an effective targeted treatment for this disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHypersensitivityEosinophiliaChildHumansTranscription FactorsGain of Function MutationSTAT6 Transcription FactorTh2 Cells

Stichwörter der Autor:innen

Inborn errors of immunityJakinibsJanus kinase inhibitorsSTAT6gain-of-function mutationprimary atopic disorders

Substanzen

Transcription FactorsSTAT6 Transcription FactorSTAT6 protein, human

Autor:innen und Institutionen

  • Division of Pediatric Allergy and Immunology School of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; The Isil Be…
  • Division of Immunology, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass.
  • Department of Experimental Pathology, Immunology, and Microbiology, American University of Beirut, Beirut, Lebanon; Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut,…
  • TUBITAK Marmara Research Center, Gene Engineering and Biotechnology Institute, Gebze, Turkey.
  • Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Department of Pathology, School of Medicine, Marmara University, Istanbul, Turkey.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • Scientific and Technological Research Council of Turkey
  • NIAID

Zitieren

APA

Baris, S., Benamar, M., Chen, Q., Catak, M. C., Martínez-Blanco, M., Wang, M., Fong, J., Massaad, M. J., Sefer, A. P., Kara, A., Babayeva, R., Eltan, S. B., Yucelten, A. D., Bozkurtlar, E., Cinel, L., Karakoc-Aydiner, E., Zheng, Y., Wu, H., Ozen, A., …, & Chatila, T. A. (2023). Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6. Journal of Allergy and Clinical Immunology, 152(1), 182-194.e7. https://doi.org/10.1016/j.jaci.2023.01.023

Vancouver

Baris S, Benamar M, Chen Q, Catak MC, Martínez-Blanco M, Wang M, et al. Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6. Journal of Allergy and Clinical Immunology. 2023;152(1):182-194.e7. doi:10.1016/j.jaci.2023.01.023

BibTeX
@article{Baris2023,
  author = {Baris, Safa and Benamar, Mehdi and Chen, Qian and Catak, Mehmet Cihangir and Martínez-Blanco, Mónica and Wang, Muyun and Fong, Jason and Massaad, Michel J and Sefer, Asena Pinar and Kara, Altan and Babayeva, Royala and Eltan, Sevgi Bilgic and Yucelten, Ayse Deniz and Bozkurtlar, Emine and Cinel, Leyla and Karakoc-Aydiner, Elif and Zheng, Yumei and Wu, Hao and Ozen, Ahmet and Schmitz-Abe, Klaus and Chatila, Talal A},
  title = {Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {1},
  pages = {182--194.e7},
  doi = {10.1016/j.jaci.2023.01.023}
}
Kostenlos starten →